Annual report pursuant to Section 13 and 15(d)

Quarterly Financial Information (unaudited) - Additional information (Details)

v3.20.4
Quarterly Financial Information (unaudited) - Additional information (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Oct. 21, 2020
Mar. 31, 2019
Dec. 31, 2020
Sep. 30, 2019
Sep. 30, 2019
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2015
Licensing and other arrangements                    
Revenue recognized           $ 27,941 $ 17,276      
Novartis International | License Agreement                    
Licensing and other arrangements                    
Revenue recognized $ 25,000   $ 25,000     25,000 0   $ 10,000 $ 37,000
Rezolute | License Agreement and Common Stock Purchase Agreement                    
Licensing and other arrangements                    
Revenue recognized   $ 2,500   $ 6,000 $ 14,000 0 14,000 $ 1,800    
Janssen Biotech Inc. | License Agreement                    
Licensing and other arrangements                    
Revenue recognized       $ 2,500   $ 400 $ 2,500